Sera Prognostics, Inc. (SERA)
2.08
+0.06
(+3.23%)
USD |
NASDAQ |
Nov 05, 16:00
2.06
-0.02
(-0.96%)
After-Hours: 20:00
Sera Prognostics SG&A Expense (TTM) : 18.50M for Sept. 30, 2026
SG&A Expense (TTM) Chart
Historical SG&A Expense (TTM) Data
| Date | Value |
|---|---|
| September 30, 2026 | 18.50M |
| June 30, 2026 | 24.17M |
| March 31, 2026 | 23.64M |
| December 31, 2025 | 23.25M |
| September 30, 2025 | 23.82M |
| June 30, 2025 | 23.52M |
| March 31, 2025 | 22.42M |
| December 31, 2024 | 21.90M |
| September 30, 2024 | 20.59M |
| June 30, 2024 | 19.86M |
| March 31, 2024 | 22.82M |
| December 31, 2023 | 24.69M |
| September 30, 2023 | 26.66M |
| June 30, 2023 | 29.06M |
| Date | Value |
|---|---|
| March 31, 2023 | 29.75M |
| December 31, 2022 | 31.48M |
| September 30, 2022 | 34.03M |
| June 30, 2022 | 33.72M |
| March 31, 2022 | 29.78M |
| December 31, 2021 | 24.42M |
| September 30, 2021 | 14.94M |
| June 30, 2021 | 10.96M |
| March 31, 2021 | 8.928M |
| December 31, 2020 | 7.538M |
| September 30, 2020 | 7.538M |
| June 30, 2020 | 4.78M |
| March 31, 2020 | 2.247M |
SG&A Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
SG&A Expense (TTM) Benchmarks
| Myriad Genetics, Inc. | 401.00M |
| BioRestorative Therapies, Inc. | 5.181M |
| CareDx, Inc. | 264.45M |
| Natera, Inc. | 1.255B |
| Exagen, Inc. | 48.45M |